Imagine a gathering where the most groundbreaking ideas in autism research are shared, debated, and expanded upon—this is what the Day of Learning event offers. But here's where it gets controversial: as science advances, some argue that certain discoveries challenge traditional perspectives on autism, sparking important conversations about how we understand and support those on the spectrum. The 13th installment of this influential event is scheduled to be held in person on March 26, 2026, in the vibrant heart of New York City, specifically at 583 Park Avenue. This gathering promises to bring together leading experts to explore the latest developments in autism science.
During this year’s Day of Learning, attendees will have the opportunity to engage with a lineup of prominent speakers who will cover a diverse range of cutting-edge topics:
- Josh Gordon, affiliated with Columbia University and the NIH, will delve into the evolving landscape of autism research, discussing what recent shifts mean for scientists, clinicians, and families.
- Helen Tager-Flusberg from Boston University will shed light on the efforts of autism scientists speaking out and pushing back against misconceptions or outdated notions.
- David Mandell, from the University of Pennsylvania, will explore the potential of federally-funded ADSI studies and their promising impact on understanding autism.
- John Spiro from the Simons Foundation will present findings on confirming and categorizing new autism subtypes, a crucial step toward personalized approaches.
- Stephan Sanders, linked with Oxford University and UCSF, will explore the promising future of genetic medicines and how they might revolutionize autism treatment.
- Diana Schendel from Drexel University will discuss research into how autism recurs within families beyond the immediate generation, offering insights into inheritance and risk factors.
Reflecting back on the 12th Day of Learning, several notable topics were covered, illustrating the breadth and depth of current autism research:
- Dr. Allyson Berent from Angelman Syndrome Therapeutics discussed advances in gene editing and therapies tailored for genetically-defined forms of autism.
- Dr. Robert Schultz from the University of Pennsylvania highlighted the innovative use of AI tools to better understand autism.
- Dr. David Amaral from UC Davis explained how post-mortem brain tissue is shedding light on the crucial role families play in autism research.
- Dr. Rebeca Levy at Stanford explored the use of organoids and assembloids—miniature, lab-grown brain models—for developing personalized treatments for severe autism.
- Dr. Elena Tenenbaum from Duke University shared how AI is being used to decode early developmental stages in infants, aiming for earlier diagnosis and intervention.
- Dr. Heather Nuske from the University of Pennsylvania discussed the use of wearable technology to reduce extreme behaviors in students with profound autism, offering promising new strategies for caregivers.
This ongoing series continuously pushes the boundaries of what we know about autism and how best to support those affected. It raises important questions—like how reliable are genetic markers in predicting autism subtypes? Or, could emerging technologies such as AI really transform early intervention strategies? We invite you to share your thoughts—do you agree with the scientific directions being pursued, or do you see potential pitfalls? Join the conversation and help shape the future of autism research.
